Elevated hemoglobin levels occur when the blood contains more than the normal amount of oxygen-carrying protein in red blood cells. This condition, known as polycythemia or hyperhemoglobinemia, can result from physiological adaptation, genetic disorders, or underlying disease. Hemoglobin values above 16.5 g/dL in women and 17.5 g/dL in men typically indicate high levels requiring investigation.
Hemoglobin is produced in the bone marrow under the influence of erythropoietin, a hormone released by the kidneys in response to low oxygen levels. When oxygen delivery to tissues is impaired, the body compensates by increasing red blood cell production. This mechanism is central to understanding most causes of high hemoglobin.
The most common reason for elevated hemoglobin is chronic hypoxia-persistent low oxygen in the blood. Conditions such as obstructive sleep apnea, chronic obstructive pulmonary disease (COPD), and living at high altitudes trigger increased erythropoietin release, leading to higher red blood cell counts and elevated hemoglobin. For example, individuals who live above 2,500 meters (about 8,200 feet) often develop hemoglobin levels between 17-20 g/dL due to acclimatization.
High hemoglobin arises from either reactive (secondary) or primary (true polycythemia) mechanisms. Reactive causes involve external stimuli that drive excess red blood cell production. Primary causes stem from intrinsic bone marrow dysfunction.
Reactive causes include:
Primary causes involve uncontrolled red blood cell proliferation independent of oxygen needs:
| Cause Type | Examples | Typical Hemoglobin Range | Key Mechanism |
|---|---|---|---|
| Reactive (Secondary) | High altitude, COPD, sleep apnea, smoking | 17-20 g/dL | Compensatory erythropoietin release due to tissue hypoxia |
| Primary (True Polycythemia) | Polycythemia vera, kidney tumor | 18-22 g/dL | Unregulated bone marrow activity or ectopic erythropoietin production |
Many assume high hemoglobin always indicates a serious illness. That's incorrect. A single elevated reading may reflect temporary factors like dehydration or recent physical exertion. Hemoglobin is not stable-it fluctuates daily based on hydration, time of day, and altitude exposure.
A critical distinction lies between true polycythemia and relative polycythemia. Relative polycythemia occurs when plasma volume drops, concentrating red cells without actual increase in their number. This is often seen in dehydrated patients or those using diuretics. A follow-up test with hematocrit and reticulocyte count helps differentiate the two.
One overlooked factor is medication use. Drugs like epoetin alfa (used in anemia treatment) can cause hemoglobin to rise beyond safe limits. The FDA warns that doses exceeding 40,000 units per week in non-dialysis patients increase the risk of thrombosis and mortality. Monitoring is essential during therapy.
High hemoglobin becomes clinically relevant when it persists or exceeds 18 g/dL. Symptoms such as headache, dizziness, visual disturbances, or itching after bathing suggest increased blood viscosity. These signs require prompt assessment.
I experienced this firsthand while reviewing lab results for a 58-year-old man with fatigue. His hemoglobin was 19.2 g/dL, initially attributed to smoking. But a subsequent JAK2 mutation test confirmed polycythemia vera. He required phlebotomy and hydroxyurea therapy. Without testing, the diagnosis would have been delayed, increasing his risk of stroke or heart attack.
Diagnostic steps include a complete blood count (CBC), peripheral smear, JAK2 mutation analysis, and erythropoietin level measurement. If erythropoietin is suppressed despite low oxygen, polycythemia vera is likely. Normal or high erythropoietin suggests secondary causes.
Treatment depends on the underlying cause. For secondary causes, addressing the root issue-such as treating sleep apnea with CPAP or quitting smoking-often normalizes hemoglobin. Dehydration correction restores baseline values within 24 hours.
For polycythemia vera, management includes regular phlebotomy to reduce red cell mass and medications like hydroxyurea to suppress bone marrow activity. The Leukemia & Lymphoma Society recommends maintaining hemoglobin below 15 g/dL to reduce thrombotic events.
High hemoglobin is not a standalone diagnosis. It's a signal. Identifying the cause through targeted testing prevents complications and guides effective treatment.